

[Docetaxel](#)

Essential medicine status

Section:

[8. Immunomodulators and antineoplastics](#) [8.2. Antineoplastics and supportive medicines](#) [8.2.1. Cytotoxic medicines](#)

ATC codes: [L01CD02](#)

Indication

Malignant neoplasms of prostate ICD11 code: [2D32.Z](#)

INN

Docetaxel

Medicine type

Chemical agent

List type

Complementary

Formulations

Parenteral > General injections > IV: 20 mg per mL ; 40 mg per mL

EML status history

First added in 2011 ([TRS 965](#))

Changed in 2015 ([TRS 994](#))

Sex

All

Age

Adolescents and adults

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Tags

Cancer

Wikipedia

[Docetaxel](#)

DrugBank

[Docetaxel](#)

Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for docetaxel on the complementary list of the EML for use in treatment protocols for metastatic prostate cancer was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for metastatic prostate cancer is attached.